The Competition Commission of Pakistan (CCP) has approved the acquisition of Standpharm Pakistan (Private) Limited by Crest Garments International (Private) Limited.
CCP determined that the transaction poses no risk to market competition in the pharmaceutical or nutraceutical sectors.
According to the CCP, the acquisition is part of an internal corporate restructuring, as both companies are owned and managed by the same group of individual shareholders.
The regulator concluded that the move will not result in any change of control or management, and that existing market dynamics will remain intact.
Standpharm Pakistan is an established name in the pharmaceutical and nutraceutical markets, offering a broad portfolio across nineteen therapeutic categories such as antibiotics, vitamins, pain management, gastrointestinal and psychiatric treatments.
In contrast, Crest Garments International operates primarily in the garment manufacturing business and has no current involvement in the pharmaceutical industry.
Following a detailed review, the CCP found that the merger does not create any horizontal, vertical, or conglomerate overlaps between the two entities. It noted that Pakistan’s pharmaceutical and nutraceutical markets remain highly competitive, with moderate concentration and frequent entry of new players.
“The transaction is unlikely to reduce competition or create dominance in any relevant market,” the Commission said in its assessment. It further emphasized that the deal simply reorganizes ownership structure within the same group, leaving market competition and consumer choice unaffected.
With this clearance, the transaction moves forward as a routine intra-group restructuring, marking another example of corporate consolidation within Pakistan’s expanding life sciences sector.
